Regeneron Pharmaceuticals
Tracked across 3 events · 24 articles · First seen Jan 29, 2026 · Last active Mar 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Regeneron Pharmaceuticals, as an originator of Eylea, has reached a settlement agreement with Alvogen, resolving patent disputes. This agreement allows Alvogen to market its biosimilar, potentially impacting Regeneron's market share for Eylea.
Jan 29, 2026 · 8 articles
Business
Wolfgang Liedtke previously served as Chair of Neurology at Regeneron Pharmaceuticals, overseeing the integration of discovery into numerous clinical trials.
Feb 03, 2026 · 7 articles
Business
Teresa Montagut previously worked at Regeneron Pharmaceuticals as Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies.
Mar 11, 2026 · 9 articles
Alvogen
competitor
↔
Regeneron Pharmaceuticals
Alvogen's biosimilar competes with Regeneron Pharmaceuticals' Eylea.
Wolfgang Liedtke
former Chair of Neurology
↔
Regeneron Pharmaceuticals
Wolfgang Liedtke was previously the Chair of Neurology at Regeneron Pharmaceutic
NEWSDESK
Track Regeneron Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard